Showing results (231-240 of 336) with videos related to
Sort By:
Pageof 34
Thoracic Cancer|May 19, 2026
Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME StudyNobuyuki Yamamoto, Hirotsugu Kenmotsu, Kiichiro Ninomiya, et al.International Journal of Clinical Oncology|May 23, 2002
NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for JapaneseNobuyuki Hamajima, Keitaro Matsuo, Hiroji Iwata, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806Hideo Kunitoh, Harubumi Kato, Masahiro Tsuboi, et al.Lung Cancer (Amsterdam, Netherlands)|May 31, 2016
The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC): Results of a multicenter prospective studyKazuo Nakagawa, Hisao Asamura, Koji Tsuta, et al.Cancer Science|February 5, 2016
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancerHiroshi Mizuuchi, Kenichi Suda, Isao Murakami, et al.Lung Cancer (Amsterdam, Netherlands)|November 20, 2013
RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancerAsuki Fukatsu, Futoshi Ishiguro, Ichidai Tanaka, et al.International Journal of Oncology|October 18, 2016
MEK inhibitors against MET-amplified non-small cell lung cancerMasato Chiba, Yosuke Togashi, Shuta Tomida, et al.Anticancer Research|March 25, 2010
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancerToshiaki Takahashi, Nobuyuki Yamamoto, Toshihiro Nukiwa, et al.Cells|September 13, 2025
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon <i>EGFR</i> Mutations-An In Vitro StudyHana Oiki, Kenichi Suda, Akira Hamada, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 20, 2025
Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III non-small cell lung cancer in Japan: A Multicenter Prospective Study (AYAME)Hirotsugu Kenmotsu, Yoshinobu Saito, Kiichiro Ninomiya, et al.Pageof 34